https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Blood 2006 Mar;107(5):1818-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Blood 2006 Mar;107(5):1818-272005-11-01 00:00:002019-02-15 09:15:15Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-62005-11-01 00:00:002019-02-15 09:19:54Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7692-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7692-92005-11-01 00:00:002019-02-15 09:19:56Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3709-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3709-142005-11-01 00:00:002019-02-15 09:23:49Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6B):4225-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6B):4225-302005-11-01 00:00:002019-02-15 08:53:28Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Int J Hyperthermia 2005 Nov;21(7):649-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Int J Hyperthermia 2005 Nov;21(7):649-562005-11-01 00:00:002019-02-15 10:00:37Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Clin. Exp. Immunol. 2005 Nov;142(2):362-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Clin. Exp. Immunol. 2005 Nov;142(2):362-92005-11-01 00:00:002019-02-15 08:37:44Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7891-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7891-9002005-11-01 00:00:002019-02-15 08:38:18Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-82005-10-28 00:00:002019-02-15 09:00:17Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-27 / Cancer Immunol. Immunother. 2006 Jan;55(1):63-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-27 / Cancer Immunol. Immunother. 2006 Jan;55(1):63-72005-10-27 00:00:002019-02-15 09:17:04Dendritic cell-based cancer immunotherapy targeting MUC-1
